Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164875 | 0.84 | TSHR (0.39) | MEN1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL30881973 | 0.84 | TSHR (0.39) | MEN1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL14241246 | 0.84 | L3MBTL1 (0.33) | HTR7L3MBTL1CA1CA2CA5A | |
| SCHEMBL14227134 | 0.81 | HTR7 (0.35) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL29471353 | 0.80 | HTR7 (0.38) | NPSR1HTR7L3MBTL1ALDH1A1CA1 | |
| SCHEMBL615592 | 0.80 | HTR7 (0.38) | NPSR1HTR7L3MBTL1ALDH1A1CA1 | |
| SCHEMBL3399136 | 0.77 | HTR7 (0.36) | SMN1; SMN2LMNAKDM4EHTR7L3MBTL1 | |
| SCHEMBL7524628 | 0.77 | TSHR (0.39) | MEN1KMT2ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL9804688 | 0.77 | HTR7 (0.36) | SMN1; SMN2LMNAKDM4EHTR7L3MBTL1 | |
| SCHEMBL14388549 | 0.77 | TSHR (0.36) | MEN1KMT2ASMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5387725-A | Chlorinating compounds having acidic protons with a perchloro-alkane and aqueous base in the presence of a tetraalkyl-ammonium hydroxide phase transfer catalyst | THE DOW CHEMICAL COMPANY (US) | 1995-02-07 | — | — | US | claimed |
| EP-0611366-A1 | CHLORINATION PROCESS, ALKYLATION OF PRODUCTS OF SAID PROCESS AND SOME PRODUCTS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1994-08-24 | — | — | EP | claimed |
| WO-1993009074-A2 | CHLORINATION PROCESS, ALKYLATION OF PRODUCTS OF SAID PROCESS AND SOME PRODUCTS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1993-05-13 | — | — | WO | claimed |
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| EP-2034998-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-5578737-A | SUBSTITUTED FLUORENES, MONOMERS FOR HIGH PERFORMANCE POLYMERS | THE DOW CHEMICAL COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| US-5387725-A | Chlorinating compounds having acidic protons with a perchloro-alkane and aqueous base in the presence of a tetraalkyl-ammonium hydroxide phase transfer catalyst | THE DOW CHEMICAL COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | CETP, NPC1, CES1 | MEN1 4200/4885KMT2A 2353/4885SMN1; SMN2 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.